格隆汇12月4日｜卫光生物公告，公司拟签署《血液制品技术合作合同》，并针对部分血液制品的技术 许可和技术转移作出相关约定。其中，技术许可费用1,200万美元，技术转移服务费400万美元，以上总 计1,600万美元，折合人民币约11,321万元。公司与合作方不存在关联关系，本次交易不属于关联交易， 不构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次交易金额在董事会审批权限范围 内，无需提交公司股东会审议。 ...

卫光生物公告称，拟与合作方签订《血液制品 技术合作合同》，涉及部分血液制品的技术许可和技术 转移，费用总计1600万美元，折合人民币约1.13亿元。合同标的为6个血液制品品种生产技术许可及服 务，许可区域内4个生产基地可使用。交易不构成重大资产重组，在董事会审批权限内。合同履行预计 对经营成果有积极影响，但可能受人员、设施、汇率等因素影响。 ...

Group 1: Company Control and Financing - The change in company control is pending approval from relevant authorities and has not yet occurred, ensuring no impact on future financing projects [2][3] - The company has committed that it will not take actions to change control or adjust fundraising projects without proper procedures [3] Group 2: Plasma Supply and Production Capacity - The company aims to build a 1,200-ton intelligent industrial base, with a projected compound annual growth rate (CAGR) of plasma collection at 8.67% from 2013 to 2024 [2] - By 2031, the annual plasma collection is expected to reach approximately 1,000 tons, and by 2033, it is projected to reach about 1,180 tons, which will meet the needs of the new industrial base [3] Group 3: Expansion of Plasma Stations - The company has received approvals to establish new plasma stations in multiple provinces, pending completion of all necessary regulatory procedures [3] Group 4: Market Competition and Product Development - The domestic blood product market still has significant growth potential despite competition from recombinant products, which currently serve as supplements to traditional blood products [3] - The company is actively enhancing its R&D capabilities and monitoring industry trends to expedite the launch of new products and technologies [3] Group 5: Research and Development Projects - Ongoing R&D projects include new intravenous immunoglobulin, fibrin adhesive, plasminogen, and antithrombin III, with updates available in the company's disclosed reports [3]

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第三次临时股东会的 法律意见书 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于深圳市卫光生物制品股份有限公司 2025 年第三次临时股东会的 法律意见书 致：深圳市卫光生物制品股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受深圳市卫光生物 制品股份有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 年第 三次临时股东会（以下简称"本次股东会"），并根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）等法律、 法规和规范性文件以及现行有效的《深圳市卫光生物制品股份有限公司章程》（以 下简称"《公司章程》"）的相关规定，对本次股东会相关法律事项进行见证并 出具本法律意见书。公司已向本所提供了本所律师为出具本法律意见书所必需的 原始书面材料、副本材料、 ...

证券代码:002880 证券简称:卫光生物 公告编号:2025-052 深圳市卫光生物制品股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1.本次股东会召开期间无否决议案的情况； 2.本次股东会未涉及变更以往股东会已通过议案的情况。 一、会议召开和出席情况 （二）会议出席情况 （一）会议召开情况 1.会议召开时间： （1）现场会议：2025 年 11 月 27 日 14:30。 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 11 月 27 日 9:15–9:25、9:30–11:30、13:00–15:00；通过深圳证券交易所互联网投票 系统投票的时间为 2025 年 11 月 27 日 9:15 至 15:00。 2.现场会议召开地点：广东省深圳市光明区光明街道光侨大道 3402 号公司办公 楼 4 楼会议室。 3.会议召开方式：现场投票和网络投票相结合。 4.会议召集人：公司董事会。 5.会议的召集、召开符合《公司法》《上市公司股东会规则》《公司章程》等 的规定 ...

Core Viewpoint - The control change of Weiguang Biological (002880.SZ) has become a focal point in the regulatory review of its stock issuance to specific targets, with uncertainties surrounding the completion of necessary agreements and approvals [1][2]. Group 1: Control Change Background - In June 2023, Weiguang Biological's controlling shareholder, Guangming District State-owned Assets Supervision and Administration Commission, signed a cooperation agreement with China National Pharmaceutical Group to establish a joint venture with a 49:51 equity ratio, which would result in China National Pharmaceutical becoming the actual controller of the company [1]. - The prerequisites for this control change include signing a supplementary cooperation agreement, a non-compensatory transfer agreement, completing the registration of the joint venture, and passing state-owned assets approval and antitrust review, none of which have been completed as of now [1]. Group 2: Current Status and Commitments - The company explained that the control change has stalled due to complex negotiations involving multiple parties, and there is uncertainty regarding the future progress of this change [1]. - Recent developments indicate that both Guangming District State-owned Assets and China National Pharmaceutical have committed not to push for a control change before the issuance and listing process is completed, which is legally binding and aims to ensure stability during the issuance period [1]. - Regarding the subscription arrangement for the current issuance, China National Pharmaceutical and its affiliates have not expressed any intention to subscribe or signed relevant agreements, and Guangming District State-owned Assets has also clarified that it will not participate in this subscription [1]. Group 3: Future Control Change Risks - The company has clarified that there is no possibility of a control change during the current issuance period, and even if the control change is pursued later, China National Pharmaceutical has committed not to adjust the fundraising projects, thereby maintaining the company's independent decision-making authority in operations and management [2]. - This commitment is expected to prevent any significant adverse impact on existing business operations and fundraising projects, not constituting a substantive obstacle to the current issuance [2].

Group 1 - The company, Shenzhen Weiguang Biological Products Co., Ltd., received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific object issuance of A-shares on October 28, 2025 [1] - The company, along with relevant intermediaries, conducted a thorough review and response to the questions raised in the inquiry letter, updating the content of the fundraising prospectus and related application documents accordingly [1] - The financial data in the fundraising documents was updated in line with the company's third-quarter report for 2025, which has already been disclosed [1] Group 2 - The issuance of A-shares is subject to approval by the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, indicating uncertainty regarding the approval process and timeline [2] - The company will fulfill its information disclosure obligations based on the progress of this matter, urging investors to make cautious decisions and be aware of investment risks [2]

Core Viewpoint - The company has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a specific issuance of A-shares, and it will respond to the questions while updating the relevant application documents [1] Group 1 - The company is working with intermediaries to address the issues raised in the inquiry letter [1] - The financial data in the application documents has been updated in accordance with the disclosure of the Q3 2025 report [1] - The updated documents have been disclosed on the Giant Tide Information Network [1] Group 2 - The issuance of A-shares requires approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission [1] - The timeline for the final results of the application remains uncertain, and the company will disclose progress in a timely manner [1]

股票简称：卫光生物 股票代码：002880 向特定对象发行 A 股股票募集说明书 （修订稿） 保荐机构（主承销商） （注册地址：深圳市罗湖区红岭中路1012号国信证券大厦16-26层） 二〇二五年十一月 深圳市卫光生物制品股份有限公司 深圳市卫光生物制品股份有限公司 募集说明书 声明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所做的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性做出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益做出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 1-1-1 深圳市卫光生物制品股份有限公司 ...